McNamara Blair, Bellone Stefania, Demirkiran Cem, Max Philipp Hartwich Tobias, Santin Alessandro D
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Gynecol Oncol Rep. 2023 Jun 3;48:101218. doi: 10.1016/j.gore.2023.101218. eCollection 2023 Aug.
Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited.
A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles.
The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.
卵巢透明细胞癌（CCC）的治疗面临诸多挑战。复发性和转移性疾病的有效治疗选择仍然有限。
一名70岁复发性转移性卵巢CCC女性患者，在标准治疗和实验性治疗失败后，对帕博利珠单抗（一种靶向PD-1的单克隆抗体）和乐伐替尼（一种口服多激酶抑制剂）联合治疗产生了持久反应。在26周的治疗中，她的靶病灶缩小了40.1%。CA-125趋势证实了连续CT扫描发现的疾病负担减轻。她总体上经历了该药物联合治疗的轻度副作用，并且在10个周期内，乐伐替尼剂量从20毫克/天降至10毫克/天。
帕博利珠单抗和乐伐替尼联合治疗可能是化疗难治性卵巢CCC的一种新治疗选择。
